- Home
- USIO vs CLGN Comparison
USIO vs CLGN Comparison
Compare USIO & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- CLGN
- Stock Information
- Founded
- USIO 1998
- CLGN 2004
- Country
- USIO United States
- CLGN Israel
- Employees
- USIO N/A
- CLGN N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- CLGN Industrial Specialties
- Sector
- USIO Finance
- CLGN Health Care
- Exchange
- USIO Nasdaq
- CLGN Nasdaq
- Market Cap
- USIO 36.6M
- CLGN 37.4M
- IPO Year
- USIO N/A
- CLGN N/A
- Fundamental
- Price
- USIO $1.56
- CLGN $1.82
- Analyst Decision
- USIO Strong Buy
- CLGN Strong Buy
- Analyst Count
- USIO 2
- CLGN 2
- Target Price
- USIO $5.00
- CLGN $12.50
- AVG Volume (30 Days)
- USIO 50.2K
- CLGN 12.5K
- Earning Date
- USIO 05-14-2025
- CLGN 05-28-2025
- Dividend Yield
- USIO N/A
- CLGN N/A
- EPS Growth
- USIO N/A
- CLGN N/A
- EPS
- USIO 0.12
- CLGN N/A
- Revenue
- USIO $82,931,840.00
- CLGN $515,000.00
- Revenue This Year
- USIO $16.14
- CLGN $2,177.67
- Revenue Next Year
- USIO $13.51
- CLGN $56.52
- P/E Ratio
- USIO $13.17
- CLGN N/A
- Revenue Growth
- USIO N/A
- CLGN N/A
- 52 Week Low
- USIO $1.24
- CLGN $1.82
- 52 Week High
- USIO $2.92
- CLGN $6.75
- Technical
- Relative Strength Index (RSI)
- USIO 51.96
- CLGN 23.18
- Support Level
- USIO $1.56
- CLGN $2.00
- Resistance Level
- USIO $1.68
- CLGN $2.40
- Average True Range (ATR)
- USIO 0.09
- CLGN 0.21
- MACD
- USIO -0.01
- CLGN -0.01
- Stochastic Oscillator
- USIO 47.83
- CLGN 3.59
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.